Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug-induced metabolic bone disease

M Wolinsky-Friedland1

  • 1Associated Internists of Danbury, Connecticut, USA.

Endocrinology and Metabolism Clinics of North America
|June 1, 1995
PubMed
Summary

Certain medications can cause metabolic bone disease, leading to conditions like osteoporosis and osteomalacia. Close monitoring and interventions are crucial to manage these drug-induced bone disorders and prevent fractures.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Navigating Adrenal Disease: A Comprehensive, Practical Guide for the Clinician.

Endocrinology and metabolism clinics of North America·2026
Same journal

Adrenal Disorders in Pregnancy.

Endocrinology and metabolism clinics of North America·2026
Same journal

Diagnosis and Management of Adrenocortical Carcinoma.

Endocrinology and metabolism clinics of North America·2026
Same journal

Pheochromocytomas and Paragangliomas.

Endocrinology and metabolism clinics of North America·2026
Same journal

Hereditary Conditions Associated with Adrenocortical Carcinoma, Pheochromocytoma, and Other Adrenal Tumors: Genetic Testing and Management Recommendations.

Endocrinology and metabolism clinics of North America·2026
Same journal

Primary Bilateral Macronodular Adrenal Hyperplasia.

Endocrinology and metabolism clinics of North America·2026

Area of Science:

  • Endocrinology
  • Pharmacology
  • Bone Biology

Background:

  • Drug-induced metabolic bone disease is a significant clinical concern.
  • Disorders include osteoporosis, osteomalacia, and adynamic bone disease, affecting bone resorption, formation, and mineralization.
  • Several drug classes are implicated, including glucocorticoids, L-thyroxine, ethanol, tobacco, anticonvulsants, neuroleptics, and chemotherapeutic agents.

Purpose of the Study:

  • To review the mechanisms and clinical implications of drug-induced metabolic bone disease.
  • To highlight the spectrum of bone disorders caused by various medications.
  • To emphasize the importance of physician awareness and timely intervention.

Main Methods:

  • Literature review of drug-induced bone diseases.
  • Analysis of mechanisms affecting bone metabolism (resorption, formation, mineralization).
  • Identification of associated clinical disorders and risk factors.

Main Results:

  • Medications alter bone resorption, formation, and mineralization, leading to specific bone diseases.
  • Glucocorticoids, L-thyroxine, ethanol, tobacco, anticonvulsants, neuroleptics, and chemotherapeutics are associated with increased fracture risk and disability.
  • Physician awareness is critical for managing these risks.

Conclusions:

  • Drug-induced metabolic bone disease encompasses a range of disorders affecting bone health.
  • Close monitoring of drug dosages and interactions is essential.
  • Interventions such as nutritional support and pharmacotherapy (antiresorptives, proformation agents) can mitigate risks.

Related Experiment Videos